Repare Therapeutics Inc. (NASDAQ:RPTX) Stock Holdings Lifted by Vontobel Holding Ltd.

Vontobel Holding Ltd. lifted its position in Repare Therapeutics Inc. (NASDAQ:RPTX) by 45.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 35,000 shares of the company’s stock after buying an additional 11,000 shares during the quarter. Vontobel Holding Ltd. owned about 0.08% of Repare Therapeutics worth $46,000 as of its most recent filing with the SEC.

Separately, Stifel Financial Corp grew its holdings in Repare Therapeutics by 36.4% during the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after purchasing an additional 13,800 shares during the last quarter. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a research report on Friday, November 8th. Lifesci Capital restated a “market perform” rating on shares of Repare Therapeutics in a research note on Friday, December 13th. Stifel Nicolaus lowered their price objective on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Finally, Bloom Burton downgraded shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 10th.

Repare Therapeutics Price Performance

Shares of Repare Therapeutics stock opened at $1.29 on Friday. The firm has a 50 day simple moving average of $1.28 and a 200 day simple moving average of $2.54. Repare Therapeutics Inc. has a fifty-two week low of $1.10 and a fifty-two week high of $7.45. The firm has a market cap of $54.84 million, a P/E ratio of -0.65 and a beta of 0.88.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.